Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure

Citation
de Boer RA, Núñez J, Kozlovski P, et al. Br J Clin Pharmacol 2020;86:1346–56.